Hester Biosciences Limited has informed the Exchange about Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Divestment of Equity stake in Texas Lifesciences Private Limited, Subsidiary
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences' board approved selling 43.81% of its 54.81% stake in subsidiary Texas Lifesciences Private Limited (TLPL) to Ticop Life Private Limited, a firm linked to TLPL's existing promoters, for a total consideration of INR 92 million. The deal was agreed on 5 March 2026 and is expected to complete within three months. After the sale, Hester will retain an 11% stake in TLPL, which will cease to be its subsidiary. TLPL reported a turnover of INR 285.89 million and net worth of INR 134.17 million in FY25, but more than 97% of its sales were to Hester itself and were eliminated in consolidated accounts, indicating TLPL functioned largely as a captive unit rather than an external revenue driver.
This is a routine subsidiary rationalisation with a minimal financial impact, since TLPL's contribution to consolidated revenue was already negligible. Shareholders are unlikely to see a material effect on earnings or stock price, though the company does give up a controlling interest in the unit.